Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07ISL
|
||||
Former ID |
DNC013670
|
||||
Drug Name |
D-210
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C23H35N5OS
|
||||
Canonical SMILES |
CCCN(CCN1CCN(CC1)C2=CC=CC=C2OC)C3CCC4=C(C3)SC(=N4)N
|
||||
InChI |
1S/C23H35N5OS/c1-3-10-27(18-8-9-19-22(17-18)30-23(24)25-19)14-11-26-12-15-28(16-13-26)20-6-4-5-7-21(20)29-2/h4-7,18H,3,8-17H2,1-2H3,(H2,24,25)
|
||||
InChIKey |
WIZIUHWXARABLD-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | D(3) dopamine receptor | Target Info | Inhibitor | [1] | |
D(2) dopamine receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Dopaminergic synapsehsa04015:Rap1 signaling pathway | |||||
cAMP signaling pathway | |||||
Gap junction | |||||
Dopaminergic synapse | |||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Dopamine receptor mediated signaling pathway | |||||
Nicotine pharmacodynamics pathway | |||||
Reactome | Dopamine receptors | ||||
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors | |||||
G alpha (i) signalling events | |||||
WikiPathways | Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
Nicotine Activity on Dopaminergic Neurons | |||||
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction | |||||
Genes and (Common) Pathways Underlying Drug Addiction | |||||
References | |||||
REF 1 | J Med Chem. 2008 May 22;51(10):3005-19. Epub 2008 Apr 12.Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.